

Ustekinumab (Stelara®)

Selected References:

- Alsenaid A, Prinz JC. 2016. Inadvertent pregnancy during ustekinumab therapy in a patient with plaque psoriasis and impetigo herpetiformis. *J Eur Acad Dermatol Venereol*. 30(3):488-90.
- American Academy of Pediatrics. 2018. Report of the Committee of Infectious Disease. RedBook. p704.
- Andrulonis R, Ferris LK. 2012 Treatment of severe psoriasis with ustekinumab during pregnancy. *J Drugs Dermatol*. 11(10):1240.
- Avni-Biron, I., et al. 2022. Ustekinumab during pregnancy in patients with inflammatory bowel disease: a prospective multicentre cohort study. *Alimentary pharmacology & therapeutics*, 56(9), 1361-1369.
- Beaulieu D, et al. 2018. Use of Biologic Therapy by Pregnant Women with Inflammatory Bowel Disease does Not affect Infant Response to Vaccines. *Clin Gast & Hep*; 16:99-105.
- Chaparro Sanchez M, et al. 2022. Live vaccines in children exposed to biological agents for IBD in utero and/or during breastfeeding: Are they safe? Results from the Dumbo registry of GETECCU. *United European Gastroenterol J* 2022;10:757-8.
- Chugh, R., et al. 2024. Maternal and Neonatal Outcomes in Vedolizumab- and Ustekinumab-Exposed Pregnancies: Results From the PIANO Registry. *The American journal of gastroenterology*, 119(3), 468-476.
- Ernest-Suarez, K., et al. 2024. Live Rotavirus Vaccination Appears Low-risk in Infants Born to Mothers With Inflammatory Bowel Disease on Biologics. *Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association*, S1542-3565(24)00677-3.
- Fitzpatrick, T., et al. 2023. Immunological effects and safety of live rotavirus vaccination after antenatal exposure to immunomodulatory biologic agents: a prospective cohort study from the Canadian Immunization Research Network. *The Lancet. Child & adolescent health*, 7(9), 648-656.
- Fotiadou C, et al. 2012. Spontaneous abortion during ustekinumab therapy. *J Dermatol Case Rep*. 6(4):105-107.
- Galli-Novak E, et al. 2016. Successful pregnancy outcome under prolonged ustekinumab treatment in a patient with Crohn's disease and paradoxical psoriasis. *J Eur Acad Dermatol Venereol*. 30(12):e191-e192.
- Galluzzo M, et al. 2019. Psoriasis in pregnancy: case series and literature review of data concerning exposure during pregnancy to ustekinumab. *J Dermatolog Treat*. 2019 Feb;30(1):40-44.
- Gisbert J, Chaparro M. 2020. Safety of New Biologics (Vedolizumab and Ustekinumab) and Small Molecules (Tofacitinib) During Pregnancy: A Review. *Drugs* 2020 Jul; 80(11):1085-1100.
- Gorodensky, J. H., Bernatsky, S., Afif, W., St-Pierre, Y., Fillion, K. B., & Vinet, É. (2023). Assessing Serious Infections in Children Exposed In Utero to Ustekinumab. *The Journal of rheumatology*, jrheum.2022-1271.
- Gotestam Skorpen C, et al. 2016. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. *Ann Rheum Dis*. 75:795-810.
- Grosen, A., et al. 2022. Normal Sperm DNA Integrity in Patients With Inflammatory Bowel Disease on Ustekinumab Maintenance Therapy. *Inflammatory bowel diseases*, 28(10), 1603-1606.
- Jeong, Y. D. et al. 2024. Biologics Use for Psoriasis during Pregnancy and Its Related Adverse Outcomes in Pregnant Women and Newborns: Findings from WHO Pharmacovigilance Study. *International archives of allergy and immunology*, 1-15.
- Julsgaard, M., et al. 2025. Infant Ustekinumab Clearance, Risk of Infection, and Development After Exposure During Pregnancy. *Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association*, 23(1), 134-143.
- Klenske E, et al. 2019. Drug Levels in the Maternal Serum, Cord Blood and Breast Milk of a Ustekinumab-Treated Patient with Crohn's Disease. *J Crohns Colitis*. 2019 Feb 1;13(2):267-269.
- Lund T and Thomsen SF. 2017. Use of TNF-inhibitors and ustekinumab for psoriasis during pregnancy: a patient series. *Dermatologic Therapy* 30:e12454.

- Mahadevan U, et al. 2017. Drug Safety and Risk of Adverse Outcomes for Pregnant Patients With Inflammatory Bowel Disease. *Gastroenterology*. 152(2):451-462.e2.
- Mahadevan U, et al. 2019. Inflammatory Bowel Disease in Pregnancy Clinical Care Pathway: A Report From the American Gastroenterological Association IBD Parenthood Project Working Group. *Amer J of Obstetrics and Gynecology*. 2019 April; 220(4):308-323.
- Mahadevan, U., et al. 2022. Pregnancy outcomes following periconceptional or gestational exposure to ustekinumab: Review of cases reported to the manufacturer's global safety database. *Alimentary pharmacology & therapeutics*, 56(3), 477-490. <https://doi.org/10.1111/apt.16960>
- Martin PL, et al. 2010. Development in the cynomolgus macaque following administration of ustekinumab, a human anti-IL-12/23p40 monoclonal antibody, during pregnancy and lactation. *Birth Defects Res B Dev Reprod Toxicol*. 89(5):351-363.
- Matro R, et al. 2018. Exposure concentrations of infants breastfed by women receiving biologic therapies for inflammatory bowel disease and effects of breastfeeding on infections and development. *Gastroenterology* 155:696-704.
- Meserve, J., 2021. Paternal Exposure to Immunosuppressive and/or Biologic Agents and Birth Outcomes in Patients With Immune-Mediated Inflammatory Diseases. *Gastroenterology*, 161(1), 107-115.e3.
- Meyer, A., et al. 2025. Safety of Vedolizumab and Ustekinumab Compared With Anti-TNF in Pregnant Women With Inflammatory Bowel Disease. *Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association*, 23(1), 144-153.e22.
- Mitrova, K., et al. 2022. Safety of Ustekinumab and Vedolizumab During Pregnancy-Pregnancy, Neonatal, and Infant Outcome: A Prospective Multicentre Study. *Journal of Crohn's & colitis*, 16(12), 1808-1815.
- Prentice, R., et al. 2025. Vedolizumab and Ustekinumab Levels in Pregnant Women With Inflammatory Bowel Disease and Infants Exposed In Utero. *Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association*, 23(1), 124-133.e7
- Rocha K, et al. 2015. Pregnancy during ustekinumab treatment for severe psoriasis. *Dermatology*; 231:103-104.
- Rosen M, et al. 2012. A case of ustekinumab for the treatment of Crohn's disease during pregnancy [abstract]. *Amer J Gastroenterol*. 107(suppl 1):S516.
- Rowan CR, et al. 2018. Ustekinumab drug levels in maternal and cord blood in a woman with Crohn's Disease treated until 33 weeks of gestation. *Journal of Crohn's and Colitis*;376-378
- Sánchez-García, V., et al. 2023. Exposure to biologic therapy before and during pregnancy in patients with psoriasis: Systematic review and meta-analysis. *Journal of the European Academy of Dermatology and Venereology : JEADV*, 37(10), 1971-1990.
- Sheeran C, Nicolopoulos J. 2014. Pregnancy outcomes of two patients exposed to ustekinumab in the first trimester. *Australasian J of Dermatology*; 55(3):235-236.
- Wils P, et al. 2021. Safety of ustekinumab or vedolizumab in pregnant inflammatory bowel disease patients: a multicentre cohort study. *Aliment Pharmacol Ther*; 53(4):460-470.

Des questions? Appelez le 866.626.6847 | Envoyez un SMS au 855.999.3525 | Envoyez un e-mail ou discutez sur [MotherToBaby.org](https://www.mothertobaby.org).

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, 1 janvier 2025.

Ustekinumab (Stelara®)

Selected References:

- Anderson JL, et al. 2014. Congenital lymphocytic choriomeningitis virus: when to consider the diagnosis. *J Child Neurol* 29(6):837-42.
- Barton LL and Mets MB. 2001. Congenital lymphocytic choriomeningitis virus infection: decade of rediscovery. *CID* 33:370-374.
- Barton LL, et al. 1995. Lymphocytic choriomeningitis virus: an unrecognized teratogenic pathogen. *Emerg Infect Dis* 1(4):152-153.
- Bonthius DJ. 2009. Lymphocytic choriomeningitis virus: a prenatal and postnatal threat. *Advances in Pediatrics* 56:75-86.
- Bonthius DJ. 2012. Lymphocytic choriomeningitis virus: An underrecognized cause of neurologic disease in the fetus, child and adult. *Semin Pediatr Neurol* 19:89-95.
- Bonthius DJ. 2024. Lymphocytic choriomeningitis virus injures the developing brain: effects and mechanisms. *Pediatr Res* 95(2):551-557.
- Centers for Disease Control and Prevention. 2014. Lymphocytic choriomeningitis. [Accessed 2/2021]. Available at URL: <https://www.cdc.gov/vhf/lcm/> and <https://www.cdc.gov/vhf/lcm/pdf/factsheet.pdf>.
- Childs JE, et al. 1992. Lymphocytic choriomeningitis virus infection and house mouse (*Mus musculus*) distribution in urban Baltimore. *Am J Trop Med Hyg* 47(1):27-34.
- Delaine M, et al. 2017. Microcephaly caused by lymphocytic choriomeningitis virus. *Emerg Infect Dis* 23(9):1548-1550.
- Enninga AA, et al. 2019. Lymphocytic Choriomeningitis Virus Infection Demonstrates Higher Replicative Capacity and Decreased Antiviral Response in the First-Trimester Placenta. *J Immunol Res*. Feb 7;2019:7375217. doi: 10.1155/2019/7375217. eCollection 2019.
- Ferenc T, et al. Lymphocytic choriomeningitis virus: An under-recognized congenital teratogen. *World J Clin Cases*. 2022 Sep 6;10(25):8922-8931.
- Fortin O, et al. 2024. Congenital infectious encephalopathies from the intrapartum period to postnatal life. *Semin Fetal Neonatal Med*. Epub 2024 Apr 10. PMID: 38677956.
- Hirsch MS, et al. 1974. Lymphocytic-choriomeningitis-virus infection traced to a pet hamster. *NEJM* 291(12):610-611.
- Jamieson D, et al. 2005. Lymphocytic choriomeningitis virus: An emerging obstetric pathogen. *Am J Obstet Gynecol* 194:1532-1536.
- Komrower GM, et al. 1955. Lymphocytic choriomeningitis in the newborn: probable transplacental infection. *Lancet* 1:697-698.
- Meritet JF, et al. 2009. A case of congenital lymphocytic choriomeningitis virus infection revealed by hydrops fetalis. *Prenatal Diagnosis* 20:626-627.
- Olivieri NR, et al. 2024. Transmission, seroprevalence, and maternal-fetal impact of lymphocytic

choriomeningitis virus. *Pediatr Res*; 95(2):456-463.

- Pencole L, et al. Congenital lymphocytic choriomeningitis virus: A review. *Prenat Diagn*. 2022 Jul;42(8):1059-1069.
- Schulte D, et al. 2006. Congenital lymphocytic choriomeningitis virus: an underdiagnosed cause of neonatal hydrocephalus. *The Pediatric Infectious Disease Journal* 25(6):560-562.
- Tevaeearai F, Moser L, Pomar L. Prenatal Diagnosis of Congenital Lymphocytic Choriomeningitis Virus Infection: A Case Report. *Viruses*. 2022 Nov 21;14(11):2586
- Traube E. 1973. LCM Virus research, retrospect and prospects, in *Lymphocytic Choriomeningitis Virus and Other Arenaviruses*, Lehmann-Grube F. (ed.) Berlin: Springer-Verlag, pp.3-10.
- Wright R, et al. 1997. Congenital lymphocytic choriomeningitis virus syndrome: A disease that mimics congenital toxoplasmosis or cytomegalovirus. *Pediatrics* 100(1):1-6.

Des questions? Appelez le 866.626.6847 | Envoyez un SMS au 855.999.3525 | Envoyez un e-mail ou discutez sur [MotherToBaby.org](https://www.MotherToBaby.org).

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, 1 janvier 2025.

Ustekinumab (Stelara®)

Selected References:

- Alder SP and Nigro G. 2013. Prevention of maternal-fetal transmission of cytomegalovirus. *Clinical Infectious Diseases* 57(S4):S189-S192.
- American College of Obstetricians and Gynecologists. 2015. Practice bulletin no. 151: Cytomegalovirus, parvovirus B19, varicella zoster, and toxoplasmosis in pregnancy. *Obstet Gynecol*. 125(6):1510-25.
- Azam A, et al. 2001. Prenatal diagnosis of congenital cytomegalovirus infection. *Obstet Gynecol* 97:443-448.
- Balegamire SJ, et al. 2024. Association Between Maternal Cytomegalovirus Seropositivity, Preterm Birth, and Preeclampsia in Two Cohorts From Quebec, Canada: A Mediation Analysis. *Am J Reprod Immunol*;92(4):e13941.
- Barlinn R, et al. 2022. Maternal cytomegalovirus infection and delayed language development in children at 3 years of age—a nested case-control study in a large population-based pregnancy cohort. *PLoS ONE* 17(12):e0278623.

- Boppana SB et al. 2013. Congenital cytomegalovirus infection: clinical outcome. *Clinical Infectious Diseases* 57(S4):S178-181.
- Carlson A, et al. 2010. Cytomegalovirus infection in pregnancy: Should all women be screened? *Reviews in OB & GYN*; 3(4):172-179.
- Centers for Disease Control and Prevention (CDC). 2016. Handwashing. Available at: <https://www.cdc.gov/handwashing/when-how-handwashing.html>.
- Centers for Disease Control and Prevention (CDC). 2018. Cytomegalovirus (CMV) and Congenital CMV Infection. Available at: <https://www.cdc.gov/cmv/clinical/features.html>.
- Centers of Disease Control and Prevention (CDC). 2020. About cytomegalovirus and congenital CMV infection.
- Chatzakis C, et al. 2020. Timing of primary maternal cytomegalovirus infection and rates of vertical transmission and fetal consequences. *Am J Obstet Gynecol*. 223(6):870-883.e11.
- Chiopris G, et al. 2020. Congenital Cytomegalovirus Infection: Update on Diagnosis and Treatment. *Microorganisms* Oct 1;8(10):1516.
- Cito G, et al. 2020. Can cytomegalovirus infection affect male reproductive function? Results of a retrospective single-centre analysis. *Andrologia*; 52(9):e13699.
- Diav-Citrin O, et al. 2003. Cytomegalovirus in pregnancy: primary versus secondary infection: a prospective cohort study on 208 pregnancies. *Birth Defects Res Part A Clin Mol Teratol*;67:392.
- Demmler-Harrison GJ, Miller JA. 2020. Houston Congenital Cytomegalovirus Longitudinal Study Group. Maternal cytomegalovirus immune status and hearing loss outcomes in congenital cytomegalovirus-infected offspring. *PLoS One*.15(10):e0240172.
- Enders G, et al. 2001. Prenatal diagnosis of congenital cytomegalovirus infection in 189 pregnancies with known outcome. *Prenat Diag* 21: 362-377.
- Grazia Revello M, et al. 2014. A randomized trial of hyperimmune globulin to prevent congenital cytomegalovirus. *NEJM*; 370:14: 1316-26.
- Farsimadan M, Motamedifar, 2021. The effects of human immunodeficiency virus, human papillomavirus, herpes simplex virus-1 and -2, human herpesvirus-6 and -8, cytomegalovirus, and hepatitis B and C virus on female fertility and pregnancy. *Br J Biomed Sci*;78(1):1-11.
- Feldman DM, et al. 2010. Toxoplasmosis, parvovirus and cytomegalovirus in pregnancy. *Clin Lab Med* 30(3):709-720.
- Foulon I, et al. 2008. Hearing loss in children with congenital cytomegalovirus infection in relation to maternal trimester in which the maternal primary infection occurred. *Pediatrics* 122(6):e1123-e1127.
- Fowler KB, et al. 2003. Congenital cytomegalovirus infection. *Curr Probl Pediatr Adoles Health Care* 33:70-93.
- Fowler KB. 2013. Congenital cytomegalovirus infection: audiologic outcome. *Clinical Infectious Diseases* 57(S4):S182-S184.
- Harnprecht K, et al. 2001. Epidemiology of transmission of cytomegalovirus from mother to preterm infant by breastfeeding. *Lancet* 357:513-8.
- Hughes BL, et al. 2021. Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. A Trial of Hyperimmune Globulin to Prevent Congenital Cytomegalovirus Infection. *N Engl J Med*. 385(5):436-444.
- Iwasenko JM, et al. 2011. Human cytomegalovirus infection is detected frequently in stillbirths and is associated with fetal thrombotic vasculopathy. *The Journal of Infectious Diseases* 203(11):1526-1533.
- James SH, Kimberlin DW. 2016. Advances in the prevention and treatment of congenital cytomegalovirus infection. *Curr Opin Pediatr*. 28(1):81-5.
- Kagan KO, et al. 2021. Outcome of pregnancies with recent primary cytomegalovirus infection in first trimester treated with hyperimmunoglobulin: observational study. *Ultrasound Obstet Gynecol*. 57(4):560-567.
- Kirschen GW, Burd I. 2023. Modeling of vertical transmission and pathogenesis of cytomegalovirus in pregnancy: Opportunities and challenges. *Front Virol*; 3:1106634.
- Leruez-Ville M, et al. 2020. Quantifying the Burden of Congenital Cytomegalovirus Infection With Long-term Sequelae in Subsequent Pregnancies of Women Seronegative at Their First Pregnancy. *Clin Infect Dis*.

71(7):1598-1603.

- Lipitz S, et al. 2002. Outcome of pregnancies with vertical transmission of primary cytomegalovirus infection. *Am J Obstet Gynecol*: 100:428-33.
- Mocanu AG, et al. 2024. The Impact of Latent Cytomegalovirus Infection on Spontaneous Abortion History and Pregnancy Outcomes in Romanian Pregnant Women. *Microorganisms*;12(4):731.
- Mestas E. 2016. Congenital cytomegalovirus. *Adv Neonatal Care*. 16(1):60-5.
- National CMV Foundation. 2023. *For healthcare providers*. Physician and OB-GYN Resources, National CMV Foundation, National CMV Foundation.
- National CMV Foundation. 2023. *Possible outcomes*. Congenital CMV Outcomes, National CMV Foundation, National CMV Foundation.
- Nigro G, et al. 2005. Passive immunization during pregnancy for congenital cytomegalovirus infection. *N Engl J Med* 353:1350-1362.
- Nigro G. 2017. Hyperimmune globulin in pregnancy for the prevention of congenital cytomegalovirus disease. *Expert Rev Anti Infect Ther* 15(11):977-986.
- Nigro G and Alder SP. 2013. Hyperimmunoglobulin for prevention of congenital cytomegalovirus disease. *Clinical Infectious Diseases* 57(S4):S193-S195.
- Ornoy A and Diav-Citrin O. 2006. Fetal effects of primary and secondary cytomegalovirus infection in pregnancy. *Reprod Toxicol* 21:399-409.
- Oliveira GM, et al. 2019. Detection of cytomegalovirus, herpes virus simplex, and parvovirus b19 in spontaneous abortion placentas. *J Matern Fetal Neonatal Med*.32(5):768-775.
- Page JM, et al. 2019. Stillbirth Associated With Infection in a Diverse U.S. Cohort. *Obstet Gynecol* 134(6):1187-1196.
- Pereira L, et al. 2014. Intrauterine growth restriction causes by underlying congenital cytomegalovirus infection. *J Infect Disease* 209: 1573-1584.
- Pesch MH, et al. 2021. Cytomegalovirus Infection in Pregnancy: Prevention, Presentation, Management and Neonatal Outcomes. *J Midwifery Womens Health*. 66(3):397-402.
- Pesch MH, et al. 2024. Intrauterine Fetal Demise, Spontaneous Abortion and Congenital Cytomegalovirus: A Systematic Review of the Incidence and Histopathologic Features. *Viruses*; 16(10):1552.
- Picone O, et al. 2013. A series of 238 cytomegalovirus primary infections during pregnancy: description and outcomes. *Prenatal Diag* 33: 751-758.
- El-Qushayri AE, et al 2020. Hyperimmunoglobulin therapy for the prevention and treatment of congenital cytomegalovirus: a systematic review and meta-analysis. *Expert Rev Anti Infect Ther*. Nov 30;1-9.
- Saade GR 2020. The effect of treatment of maternal CMV infection on the development of placental syndrome. *AJOG* 222(1) Supp:S2-3.
- Seidenari A, et al. 2024. Follow-Up of Infants With Congenital Cytomegalovirus Following Maternal Primary Infection in the First Trimester and Normal Fetal Brain Imaging at Midgestation. *Prenat Diagn*; 45(2):178-184.
- Simonazzi G, et al. 2018. Perinatal outcomes of non-primary maternal cytomegalovirus infection: A 15-year experience. *Fetal Diagn Ther*. 43(2):138-142.
- Sorrenti S, et al. 2025. Diagnosis and management of congenital Cytomegalovirus: Critical Appraisal of Clinical Practice Guidelines. *Eur J Obstet Gynecol Reprod Biol*; 306:172-180.
- Williams EJ, et al. 2013. Viral infections: contributions to late fetal death, stillbirth, and infant death. *J Pediatr* 163(2): 424-428.
- Yinon T et al. 2010. Cytomegalovirus infection in pregnancy. *J Obstet Gynaecol Can* 32(4):348-354.

Des questions? Appelez le 866.626.6847 | Envoyez un SMS au 855.999.3525 | Envoyez un e-mail ou discutez sur MotherToBaby.org.

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, 1 janvier 2025.

Ustekinumab (Stelara®)

Selected References:

- Ackerman JP, et al. 2010. A review of the effects of prenatal cocaine exposure among school-aged children. *Pediatrics* 125(3):554-565.
- Akyuz N, et al. 2014. Structural brain imaging in children and adolescents following prenatal cocaine exposure: preliminary longitudinal findings. *Dev Neurosci*. 316-28.
- Behnke M, et al. 2001. The search for congenital malformations in newborns with fetal cocaine exposure. *Pediatrics* 107(5):E74.
- Bracken MB, et al. 1990. Association of cocaine use with sperm concentration, motility, and morphology. *Fertil Steril* 53:315-322
- British Columbia Reproductive Care Program. 1999. Substance Use Guideline 5B: Prenatal Cocaine Exposure, Care of the Newborn. Retrieved from: www.perinatalservicesbc.ca/Documents/Guidelines-Standards/Newborn/CocaineExposureNewbornCareGuideline.pdf.
- Cestonari, C, et al. 2022. Infants of mothers with cocaine use: Review of clinical and medico-legal aspects. *Children* 9(1):67-84.
- Chiriboga C, et al. 2007. Prenatal cocaine exposures and dose-related cocaine effects on infant tone and behavior. *Neurotoxicol Teratol* 29: 323-330.
- Chiriboga CA, et al. 2009. Prenatal cocaine exposure and prolonged focus attention. Poor infant information processing ability or precocious maturation of attentional systems? *Dev Neurosci* 31(1-2):149-158.
- Cone EJ, et al. 1996. Cocaine excretion in the semen of drug users. *J Anal Toxicol* 20:139-140.
- De Genna, N. M., Goldschmidt, L., & Richardson, G. A. (2022). Prenatal cocaine exposure, early cannabis use, and risky sexual behavior at age 25. *Neurotoxicology and teratology*, 89, 107060. <https://doi.org/10.1016/j.ntt.2021.107060>
- Dos Santos JF, et al. 2018. Maternal, fetal and neonatal consequences associated with the use of crack cocaine during the gestational period: a systematic review and meta-analysis. *Arch Gynecol Obstet*. 298(3):487-503.
- Hoyme HE, et al. 1990. Prenatal cocaine exposure and fetal vascular disruption. *Pediatrics* 85:743-747.
- Jufer RA, et al. 2000. Elimination of cocaine and metabolites in plasma, saliva, and urine following repeated oral administration to human volunteers. *Journal of analytical toxicology*; 24(7), 467-477.

- Karpova N, 2021. Prenatal drug exposure and executive function in early adolescence. *Neurotoxicology and teratology*; 88, 107036.
- Landi N, et al. 2017. Prenatal Cocaine Exposure Impacts Language and Reading Into Late Adolescence: Behavioral and ERP Evidence. *Dev Neuropsychol*. 42(6):369-386.
- Levine TP, et al. 2008. Effects of prenatal cocaine exposure on special education in school-aged children. *Pediatrics* 122 (1): e83-91.
- Lewis BA, et al. 2007. Prenatal cocaine and tobacco effects on children's language trajectories. *Pediatrics* 120(1):e78-85.
- Mayer LC, Nicholls S. 2007. Neurocognitive development in middle-school age and adolescent prenatally cocaine-exposed children. *Birth Def Res (Part A)* 79:381-394.
- Modernel XD, et al. 2017. Use of crack in pregnancy: repercussions for the newborn. *Invest Educ Enferm*. 35(3).
- Montgomery DP, et al. 2008. Using umbilical cord tissue to detect fetal exposure to illicit drugs: a multicentered study in Utah and New Jersey. *J Perinatol* 28(11):750-753.
- Morie KP, et al. 2020. Alexithymia, Emotion-Regulation Strategies, and Traumatic Experiences in Prenatally Cocaine-Exposed Young Adults. *The American journal on addictions*; 29(6), 492-499.
- National Institute on Drug Abuse. "Substance Use While Pregnant and Breastfeeding." *National Institute on Drug Abuse*, 2020,
- National Library of Medicine (US), 2006. "Cocaine"
- Ness RB, et al. 1999. Cocaine and tobacco use and the risk of spontaneous abortion. *N Engl Med* 340(5):333-339.s
- Oliveira TA, et al. 2016. Perinatal outcomes in pregnant women users of illegal drugs. *Rev Bras Ginecol Obstet*. 38(4):183-188.
- Pires A, et al 2012. Repeated inhalation of crack-cocaine affects spermatogenesis in young and adult mice. *Inhal Toxicol*. 24(7):439-446.
- Reece-Stremtan S, Marinelli KA. 2015. ABM clinical protocol #21: guidelines for breastfeeding and substance use or substance use disorder, revised 2015. *Breastfeed Med*. 10(3):135-41.
- Richardson GA, et al. 2007. Effects of prenatal cocaine exposure on growth: a longitudinal analysis. *Pediatrics*. 120(4): e1017-1027.
- Richardson GA, et al. 2010. Prenatal cocaine exposure: Effects on mother- and teacher-rated behavior problems and growth in school-age children. *Neurotoxicol Teratol*.
- Richardson GA, et al. 2015. Effects of prenatal cocaine exposure on adolescent development. *Neurotoxicol Teratol*. 49:41-8.
- Roussotte F, et al. 2010. Structural, metabolic, and functional brain abnormalities as a result of prenatal exposure to drugs of abuse: evidence from neuroimaging. *Neuropsychol Rev*.
- Salzwedel A, et al. 2020. Functional dissection of prenatal drug effects on baby brain and behavioral development. *Human brain mapping*; 41(17), 4789-4803.
- Semet M, et al. 2017. The impact of drugs on male fertility: a review. *Andrology* 5:640-63.
- Serino D, et al. 2018. Psychological Functioning of Women Taking Illicit Drugs during Pregnancy and the Growth and Development of Their Offspring in Early Childhood. *J Dual Diagn*. 25:1-13.
- Singer LT, et al. 2000. Neurobehavioral outcomes of cocaine-exposed infant. *Neurotoxicol Teratol* 22(5):653-666.
- Singer LM, et al. 2008. Prenatal cocaine exposure: drug and environmental effects at 9 years. *J Pediatr* 153(1): 105-111.
- Van Gelder MMHJ, et al. 2009. Maternal periconceptional illicit drug use and the risk of congenital malformations. *Epidemiology* 20(1):60-66.
- Weathers WT, et al. 1993. Cocaine use in women from a defined population: prevalence at delivery and effects of growth in infants. *Pediatrics* 91(2):326-239.
- Yazigi RA, et al. 1991. Demonstration of specific binding of cocaine to human spermatozoa. *JAMA* 266:1956-1959.

Des questions? Appelez le 866.626.6847 | Envoyez un SMS au 855.999.3525 | Envoyez un e-mail ou discutez sur MotherToBaby.org.

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, 1 janvier 2025.

Ustekinumab (Stelara®)

- Akorn Operating Company LLC. 2023. Olopatadine product label. Available at: <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f42d26f8-c583-411b-b17f-b3ca9eaba7a2>. Accessed 30 September 2024.

Des questions? Appelez le 866.626.6847 | Envoyez un SMS au 855.999.3525 | Envoyez un e-mail ou discutez sur MotherToBaby.org.

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, 1 janvier 2025.